Published in Cancer Weekly, December 7th, 2004
Ligand's total revenues for the third quarter of 2004 were $49.5 million, compared to $31.3 million for the same period in 2003, an increase of 58%. Net loss for the third quarter of 2004 was $6.8 million ($.09 per share), compared to a net loss of $11.1 million ($.16 per share) for the same period in 2003, an improvement of 39% (44%...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.